RA CAPITAL MANAGEMENT, LLC
Q1 2014 13F-HR Holdings
Net value change ($000)
+535,941
(62.4%)
New positions
7
Sold out positions
2
Turnover %
21.3%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2013
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| Dicerna Pharmaceuticals Inc | 68,607 | NEW |
| ENTA | 61,628 | NEW |
| DYAX CORP | 54,576 | 447.2% |
| Arrowhead Pharma Inc | 26,072 | 117.3% |
| *REPROS THERAPEUTICS INC | 25,529 | NEW |
| SGMO | 21,808 | 30.0% |
| NBIX | 18,822 | NEW |
| PRTA | 16,045 | 36.9% |
| BCRX | 12,955 | 39.2% |
| PTCT | 12,894 | 101.0% |
Top Reduces (Value $000, Stocks/ETFs)
| ACAD | -23,153 | -79.2% |
| NVAX | -10,337 | -18.7% |
| ENZO BIOCHEM INC | -6,624 | -100.0% |
| DERMA SCIENCES INC | -4,606 | -21.3% |
| OCERA THERAPEUTICS INC | -3,027 | -35.2% |
| CHELSEA THERAPEUTICS INTL LT | -2,957 | -100.0% |
| *DYNAVAX TECHNOLOGIES CORP | -2,722 | -7.8% |
| ACHILLION PHARMACEUTICALS INC | -678 | -0.9% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
420,917
(30.2% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|